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Mitochondria are key organelles in eukaryotic cells for their 
role in metabolism and other biosynthetic pathways.  They 
play a key role in the production of ATP via oxidative 
phosphorylation (OXPHOS).  Over eighty proteins make up 
the various OXPHOS complexes, (Bestwick, 2013) several of 
which are encoded by the mitochondrial genome (mtDNA). 
Mitochondria have double stranded  circular DNA molecules 
that have 37 total genes and no introns encoding OXPHOS 
complex subunits, tRNAs, and rRNAs (Alvarez, 2008).  Within 
mitochondria the processes of transcription and translation 
take place to generate these important OXPHOS subunit 
proteins.  During the process of mitochondrial transcription, 
the transcription factor TFAM (transcription factor A, 
mitochondria) is important in promoter regulation. TFAM 
activates transcription at both the light strand promoter, and 
the heavy strand promoter (Ngo, 2014). TFAM itself is a 
multifunctional mitochondrial protein in that it binds both 
specific (promoter) and nonspecific mtDNA sequences.  At 
promoter sequences the protein causes a U-turn in the DNA, 
while less dramatic bending takes places when bound 
nonspecifically.  TFAM has two high mobility groups that help 
in the process of making U-turns in the DNA (Ngo, 2014). Our 
aim is to identify novel interacting proteins with TFAM using 
a yeast-two-hybrid model. Additionally, we are interested in 
determining if there are changes in the protein interacting 
partners in mutant forms of TFAM.  Specially, two point 
mutations in the TFAM gene have been linked to late onset 
Alzheimer’s disease, S12T and P178L. The mutation S12T has 
a nucleotide change of a G to C which causes an amino acid 
change from a Ser to Thr, and the P178L has a nucleotide 
changed from a C to a T which causes an amino acid change 
from a Pro to a Leu (gene cards/ NCBI).  Biochemical and 
genetic techniques are being used to identify and characterize 
changes in protein interaction partners as a result of these 
mutations. 
TFAM gene cloning:
• PCR was used to amplify the human TFAM gene
• NcoI and SacI restriction enzymes were used to prepare the 
amplified gene and plasmid (pGEM-T Easy, Promega)
• TFAM gene then ligated with the plasmid
• Restriction digest and sequencing were used to confirm cloning 
of the TFAM gene in the pGEM-T Easy plasmid
Generation of library DNA:
• RNA was isolated from human liver cells (HepG2 cells) 
• cDNA was generated using a High Capacity cDNA Reverse 
Transcription kit (Applied Biosystems)
• cDNA within the size range of 2500-400 bp was isolated to 
generate the yeast-2-hybrid library 
All DNA products were analyzed using a 1% agarose gel with 
electrophoresis, and visualized using GelRed (Biotium).
• Site Directed mutagenesis to 
create the two point mutations 
that are Linked to Alzheimer's
• Interaction Screen using a yeast 
2 hybrid model
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Figure 4. Sample sequencing data for TFAM candidates. Both candidates 
were sequenced in the forward and reverse directions using M13 
primers. Sequencing was performed by Eurofins Genomics (Louisville, 
KY). Sequencing data as shown was analyzed and compared to the known 
sequence of TFAM Sequencing data positively confirmed both candidates 
as containing the human TFAM gene.
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